Neurocrine Biosciences NBIX
Neurocrine Biosciences is a US biopharmaceutical company that develops and commercializes innovative treatments for neurological, endocrine, and psychiatric disorders, with products such as Ingrezza and Crenessity. Neurocrine Biosciences shows solid growth (revenue +39.5%) and robust financial health (ND/EBITDA 0.08), with a promising pipeline supporting its valuation.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Neurocrine Biosciences is a US biopharmaceutical company that develops and commercializes innovative treatments for neurological, endocrine, and psychiatric disorders, with products such as Ingrezza and Crenessity. Neurocrine Biosciences shows solid growth (revenue +39.5%) and robust financial health (ND/EBITDA 0.08), with a promising pipeline supporting its valuation.
Score by category
| Category | Score |
|---|---|
| Financial health | 8.0 |
| Quality / Moat | 7.8 |
| Valuation | 6.8 |
| Growth | 8.9 |
| Dividend | 1.5 |
| Momentum | 4.7 |
| Risk & Context | 8.3 |
OVERALL SCORE: 7.1/10
Context and risks
Moderate regulatory risk in the US and pricing pressure in the pharmaceutical sector. Dependence on INGREZZA for a significant portion of revenue adds concentration risk.
News considered in the analysis
- Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit — La estrategia de diversificación es positiva, pero la pérdida de exclusividad de INGREZZA en 2029 es un viento en contra conocido y material para el crecimiento a largo plazo.
- Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story — La abundancia de datos de pipeline podría impulsar la confianza en el crecimiento futuro, aunque el impacto real dependerá de los resultados de los ensayos.
- Neurocrine Biosciences' Ingrezza, Crenessity to Drive H2 Ahead of 'Catalyst-Rich' 2027, RBC Says — El respaldo de RBC y la expectativa de catalizadores en 2027 refuerzan la tesis de crecimiento, aunque el mercado ya lo descuenta en parte.
- Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go? — El avance de Crenessity en hiperplasia suprarrenal congénita es una oportunidad de crecimiento adicional, pero su contribución a las ventas aún es incierta.
- Neurocrine Biosciences (NBIX) Wins FDA Trial Nod, Is It Still Below Fair Value? — La aprobación de la FDA para un ensayo clínico es un hito regulatorio positivo que respalda el pipeline, aunque el impacto en la valoración es moderado.
Verdict: Hold; growth and pipeline offset the long-term risk of INGREZZA loss of exclusivity.
Main risk: Revenue concentration in INGREZZA and its loss of exclusivity in 2029 is the biggest risk, despite the pipeline in development.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →